Evidence map›Paper›PMID 26337432›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2015

Rapid detection of carbapenemase activity: benefits and weaknesses of MALDI-TOF MS.

C Mirande, I Canard, S Buffet Croix Blanche, J-P Charrier, A van Belkum, M Welker, S Chatellier

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Performance of the matrix-assisted laser desorption ionization time-of-flight mass spectrometry system for rapid identification of streptococci: a review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Rapid LC-MS/MS detection of different carbapenemase types in carbapenemase-producing Enterobacterales.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  6. A Variant Carbapenem Inactivation Method (CIM) forPathogens (Basel, Switzerland) · 2022
    Article
  7. Review
  8. Carbapenemase ProducingAntibiotics (Basel, Switzerland) · 2021
    Article
  9. High-performance method to detection of Klebsiella pneumoniae Carbapenemase in Enterobacterales by LC-MS/MS.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020
    Article
  10. Direct detection of intactClinical mass spectrometry (Del Mar, Calif.) · 2020
    Article
  11. Article
  12. Detection of carbapenemase producers by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Review
  13. Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  14. Performance Evaluation of the MBT STARFrontiers in microbiology · 2019
    Article
  15. Review
  16. Review
  17. Article
  18. Comparison of MALDI-ToF MS with the Rapidec Carba NP test for the detection of carbapenemase-producing Enterobacteriaceae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Article
  19. How to manageDrugs in context · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

C MirandeMicrobiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France. caroline.mirande@biomerieux.com.
I CanardMicrobiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France.
S Buffet Croix BlancheMicrobiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France.
J-P CharrierTRD-Innovation Unit, bioMérieux SA, Marcy L'Étoile, France.
A van BelkumR&D Microbiology, bioMérieux SA, La Balme-les-Grottes, France.
M WelkerR&D Microbiology, bioMérieux SA, La Balme-les-Grottes, France.
S ChatellierMicrobiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France.
bioMérieux (Brazil) · BRbioMérieux (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) has been introduced as an identification procedure for bacteria and fungi. The MALDI-TOF MS-based analysis of resistance to β-lactam antibiotics has been applied to detect hydrolysis of carbapenems by different bacterial strains. However, the detection of enzymatic carbapenem degradation by MALDI-TOF MS lacks well-standardized protocols and several methods and models of interpretation using different calculations of ratio-of-peak intensities have been described in the literature. Here, we used faropenem and ertapenem hydrolysis as model compounds. In an attempt to propose a universal protocol, the hydrolysis was regularly monitored during 24 h using well-characterized bacterial strains producing different types of carbapenemases (KPC, IMP, NDM, VIM, and OXA-48). Variable responses and different timing for detectable hydrolysis, depending on the enzyme produced, were observed. KPC degrades its template antibiotics very quickly (15 min for some KPC producers) compared to other types of enzymes (more than 90 min for other enzymes). Prior bacterial lysis was shown to be of no interest in the modulation or optimization of the hydrolytic kinetics. The adequate detection of carbapenem hydrolysis would, therefore, require several MALDI-TOF MS readouts for the timely detection of rapid hydrolysis without missing slow hydrolysis. This enzymatic constraint limits the implementation of a standard protocol in routine microbiology laboratories.

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsErtapenemFungiHumansHydrolysisKineticsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTime FactorsAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamscarbapenemaseErtapenemfropenem

Identifiers

PMID26337432
OpenAlexW1251482461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.